Carboplatin Chemotherapy in Patients with Recurrent High-grade Glioma

Clinical Oncology

Volumn 23, Issue 1, 2011, Pages 55-61

  Murray, L J ^a   Bridgewater, C H ^a   Levy, D ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Carboplatin; Glioblastoma multiforme; High grade glioma

Indexed keywords

CARBOPLATIN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLIOMA; HUMAN; KAPLAN MEIER METHOD; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARBOPLATIN; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650417254     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.09.007     Document Type: Article

References (19)

1. Stupp R., Mason W.P., Van Den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolamide for glioblastoma. New Engl J Med 2005, 352:987-996.
2. Neider C., Mehta M.P., Jalali R. Combined radio- and chemotherapy of brain tumours in adult patients. Clin Oncol 2009, 21:515-524.
3. Brandes A.A. State-of-the-art treatment of high-grade brain tumours. Semin Oncol 2003, 30:4-9.
4. Huncharek M., Kupelnik B., Bishop D. Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Reviews 1998, 24:307-316.
5. Yung W.K., Mechtler L., Gleason M.J. Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol 1991, 9:860-864.
6. Warnick R.E., Prados M.D., Mack E.E., et al. A phase II study of intravenous carboplatin for the treatment of recurrent gliomas. J Neuro Oncol 1994, 19:69-74.
7. Twelves C.J., Ash C.M., Miles D.W., et al. Activity and toxicity of carboplatin and iproplatin in relapsed high grade glioma. Cancer Chemother Pharmacol 1991, 27:481-483.
8. Poisson M., Pereon Y., Chiras J., Delatorre J.Y. Treatment of recurrent malignant supra-tentorial glioma with carboplatin. J Euro-Oncol 1991, 10:139-144.
9. Prados M.D., Warnick R.E., Ronald E., et al. Intravenous carboplatin for recurrent gliomas: a dose escalating phase II trial. Am J Clin Oncol 1996, 19:609-612.
10. Prados M.D., Schold S.C., Fine H.A., et al. A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro-Oncol 2003, 5:96-103.
11. Chu E., DeVita V.T. Carboplatin and temozolamide. Physicians cancer chemotherapy drug manual 2005 2005, Jones and Bartlett, Sudbury, MA, 79-82, 323-325.
12. Jeremic B., Grujicic D., Jevremovic S., et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 1992, 10:1074-1077.
13. Stein M.E., Kuten A., Drumea K., Goldsher D., Tzuk-Shina Z. Carboplatin and etoposide for recurrent malignant glioma following surgical and radiotherapy failure: a clinical study conducted at the Northern Israel Oncology Centre. J Surg Oncol 1999, 71:167-170.
14. Robins H.I., Chang S.M., Prados M.D., et al. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro-Oncol 2002, 4:109-114.
15. A Report of the Medical Research Council Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: development of a prognostic index. J Neuro-oncol 1990, 9:47-55.
16. Wong E.T., Hess K.R., Gleason M.J., et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 1999, 17:2572-2578.
17. Yung W.K., Albright R.E., Olson J., et al. A phase II study of temozolamide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83:588-593.
18. Vrendenburg J., Cloughesy T., Prados M., et al. A phase II, randomized, non-comparative clinical trial of bevacizumab alone or in combination with irinotecan demonstrates prolongation of 6-month progression-free survival in recurrent, treatment-refractory glioblastoma. J Clin Oncol 2008, 26. (Suppl.);abstract 2010b.
19. Poulson H.S., Grunnet K., Sorenson M., et al. Bevacizumab plus irinotecan in the treatment of patients with progressive recurrent malignant brain tumours. Acta Oncol 2009, 48:52-58.